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AbstrACt
Introduction At least 30% of people living with HIV 
(PLWH) infection have non- alcoholic fatty liver disease 
(NAFLD), which has now become a leading cause of 
hepatic fibrosis and cirrhosis. Management is based 
largely on lifestyle modifications, which are difficult to 
achieve, and therapeutic options are urgently needed. 
Maraviroc (MVC), through antagonism of CCR5 receptors, 
may reduce hepatic fibrosis progression and could be an 
effective treatment for NAFLD. However, dosing is usually 
two times per day, unlike most currently recommended 
antiretroviral therapies. This study will investigate 
the feasibility and acceptability of addition of MVC to 
combination antiretroviral therapy in PLWH and NAFLD as 
a treatment for NAFLD.
Methods and analysis This is a phase IV, randomised, 
open- label, non- invasive feasibility study. Sixty individuals 
with well- controlled HIV-1 and NAFLD will be recruited 
from UK HIV clinics and randomised 1:1 to receive either 
optimised background therapy (OBT) plus MVC or OBT 
alone. Follow- up will be every 24 weeks for 96 weeks. 
The primary outcome measures will include recruitment 
and retention rates, adverse events and adherence. 
Secondary outcomes will include changes in markers of 
hepatic fibrosis, including the Enhanced Liver Fibrosis 
score, median liver stiffness measurement and controlled 
attenuation parameter scores on Fibroscan, and quality of 
life assessments. Analyses will be performed according 
to intention- to- treat principles. For secondary outcomes, 
estimated differences and 95% CIs between the groups 
using a t- method will be presented for continuous 
variables and as exact 95% binomial CIs for categorical 
variables.
Ethics and dissemination Ethical approval was 
obtained through the London Dulwich UK Research 
Ethics Committee (reference 17/LO/2093). Results will be 
disseminated both through community groups and peer- 
reviewed scientific literature.
trial registration number SRCTN31461655. EudraCT 
number 2017-004141-24; Pre- results.
IntroduCtIon
Recent cohorts, and a systematic review, have 
identified a prevalence of non- alcoholic 
fatty liver disease (NAFLD) in people living 
with HIV (PLWH) of between 30% and 
50%.1 2 Risk factors include those associated 
with the metabolic syndrome, in particular, 
high body mass index (BMI), type II diabetes 
mellitus and dyslipidaemia, as well as genetic 
polymorphisms. Additional HIV- related 
risk factors include immunoactivation, gut 
microbiome dysregulation and antiretroviral 
strengths and limitations of this study
 ► Investigating a novel treatment for non- alcoholic 
fatty liver disease in people living with HIV (PLWH).
 ► Simple study design ensuring ease of understanding 
for potential recruits.
 ► Non- invasive approach likely to increase acceptabil-
ity to participants.
 ► Minimal difference in frequency of follow- up from 
standard of care for PLWH.
 ► The gold standard for assessment of liver disease 
is biopsy; hence, non- invasive markers may under-
quantify or overquantify the degree of steatosis or fi-
brosis. However, a requirement for histology is likely 
to deter many potential recruits, particularly those 
unlikely to have advanced disease.
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box 1 Primary outcome measures
 ► Proportion of eligible individuals approached who are successfully 
recruited.
 ► Monthly participant recruitment rate.
 ► Participant retention in the study at 48 and 96 weeks.
 ► Proportion of participants for whom there are missing data at 48 
and 96 weeks.
 ► Proportion of participants reporting adverse events at 48 and 96 
weeks.
 ► Level of self- reported adherence to the study drug at 48 and 96 
weeks in those allocated to the maraviroc group.
box 2 secondary outcome measures
 ► Mean change in the Enhanced Liver Fibrosis score by 48 and 96 
weeks.
 ► Mean change in Fibroscan median liver stiffness measurement by 
48 and 96 weeks.
 ► Mean change in the Fibroscan controlled attenuation parameter 
score by 48 and 96 weeks.
 ► Change in the % with a CT liver:spleen attenuation ratio of <1.0 by 
96 weeks.
 ► Mean change in blood- derived biochemistry by 48 and 96 weeks: 
fasting high- density lipoprotein (HDL):cholesterol ratio, low- 
density lipoprotein, HDL, triglyceride, glucose, Hb1Ac and alanine 
aminotransferase.
 ► Mean change in clinical signs of the metabolic syndrome by 48 and 
96 weeks: body mass index, waist circumference and weight.
 ► Mean change in HIV parameters: CD4 cell count and per cent with 
undetectable HIV viral load.
 ► Differences in the quality of life of participants by 48 and 96 
weeks as assessed by responses to the chronic liver disease 
questionnaire (CLDQ) for non- alcoholic fatty liver disease, and 
the 36- Item Short Form Survey and Work Productivity and Activity 
Impairment: Specific Health Problem (WPAI:SHP) questionnaires.
therapy toxicity.3 4 Of those with NAFLD, 20%–40% will 
develop steatohepatitis, which may progress to fibrosis 
and cirrhosis.2 4 Thus, NAFLD has now become a leading 
cause of liver disease in PLWH.
Several management approaches are recommended 
for NAFLD. These include addressing underlying lifestyle 
factors, including reducing weight by ~10%, increasing 
exercise and optimising glycaemic control.5 Pharmaco-
logical interventions include vitamin E and pioglitazone.5 
However, there are few data to inform optimal interven-
tions, particularly in PLWH, which has led to increasing 
interest in novel approaches.
The chemokine CCL5/RANTES, the ligand for CCR5, 
plays a key role in hepatic inflammation and fibrosis. CCR5 
mediates intrahepatic immune cell interactions which 
promote activation and migration of Kupffer cells and 
hepatic stellate cells; these in turn promote inflammation 
and hepatic fibrosis.6 7 Antagonism of this pathway could 
therefore reduce fibrosis progression.7–9
Maraviroc (MVC) is licensed for the treatment of 
HIV-1 infection in both treatment- naïve and treatment- 
experienced individuals, where the infecting strain is 
R5 tropic, as part of combination antiretroviral therapy 
(cART).10 11 MVC inhibits the binding of HIV-1 gp120 to 
the CCR5 coreceptor, thereby preventing virus entry into 
the cell. The property of MVC antagonising CCL5- CCR5- 
mediated interactions has led to interest in its potential 
anti- inflammatory benefits, in addition to its anti- HIV 
activity, particularly in the liver and brain.12–14 Further-
more, there are over 10 years of data relating to the 
safety of MVC in humans, and the drug is well tolerated, 
including in individuals with chronic liver disease caused 
by HIV/HCV or HIV/HBV coinfection.15
In vitro, MVC reduces the release of proinflamma-
tory cytokines implicated in fibrosis from immortalised 
human hepatic stellate cells, with reduced expression of 
extracellular matrix proteins.16 MVC also reduces rates of 
hepatic fibrosis progression in mice.17
Furthermore, in an analysis of HIV/HCV- coinfected 
individuals receiving MVC- containing cART, MVC reduced 
hepatic fibrosis progression over 18 months, indicated 
through the aspartate aminotransferase (AST):platelet 
ratio index, with one of three individuals showing fibrosis 
regression.13 Transient elastography studies also demon-
strated a benefit of MVC on liver stiffness measurements in 
HIV/HCV- coinfected individuals receiving MVC.18
Finally, in a phase two study, cART- naïve PLWH were 
randomised to receiving efavirenz or the novel antiret-
roviral, cenicriviroc (CVC), an antagonist of CCR2 and 
CCR5, both in combination with tenofovir disoproxil 
fumarate- emtricitabine. Those in the CVC arm expe-
rienced a decrease in the monocyte activation marker 
sCD14.19 Furthermore, in a phase two study of CVC in 
HIV- uninfected individuals with non- alcoholic steato-
hepatitis (NASH), twice as many individuals receiving 
CVC versus placebo achieved an improvement in biopsy- 
assigned fibrosis .20
Following these observations, it is plausible that CCR5- 
receptor antagonism by MVC may reduce hepatic fibrosis 
in PLWH and NAFLD. However, no study has yet investi-
gated this.
study rAtIonAlE
In vitro data for MVC and clinical trial outcomes for CVC 
suggest CCR5 antagonism may reduce hepatic fibrosis. 
MVC is licensed for HIV-1 treatment as part of cART 
and may be an effective treatment for NAFLD in PLWH. 
However, recommended dosing is two times per day, 
which could be associated with reduced acceptability to 
PLWH and NAFLD. There is therefore a need to inves-
tigate the feasibility and acceptability of the addition of 
MVC to antiretroviral therapy in PLWH and NAFLD as a 
possible therapeutic option for NAFLD.
outCoME MEAsurEs
Primary and secondary outcome measures are shown in 
boxes 1 and 2.
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box 3 Inclusion criteria
 ► Aged 18 years and older.
 ► HIV-1 infected with durably suppressed HIV viral load (VL) (<50 cop-
ies/mL for ≥6 months).
 ► Note: one HIV VL blip (VL 50–200 copies/mL) is allowed in the 6 
months prior to screen.
 ► Has evidence of NAFLD on hepatic imaging (USS, CT or MRI) or on 
biopsy either at screen or in the 6 months prior to screen.
 ► Provides written, informed consent to participate.
 ► Is willing to comply with the protocol requirements.
 ► If female and of childbearing potential, is using effective birth con-
trol methods (as agreed by the investigator) and willing to continue 
practising these birth control measures during the trial and for at 
least 30 days after the end of the trial.
Note: Women who have been postmenopausal for at least 2 years, 
women with a total hysterectomy and women who have had a tubal 
ligation are considered of non- childbearing potential.
 ► If male and sexually active with female partners of childbearing po-
tential, is using effective barrier contraception and willing to contin-
ue using this during the trial and for at least 30 days after the end 
of the trial.
box 4 Exclusion criteria
 ► Severe cardiovascular disease, including known angina or history of 
myocardial infarction.
 ► History of postural hypotension, defined as a reduction in the sys-
tolic blood pressure of ≥20 mm Hg after standing for at least 1 min.
 ► Individuals previously exposed to maraviroc (MVC).
 ► HIV viral load (VL) detectable (>50 copies/mL).
Note: one blip (VL 50−200 copies/mL) within 6 months prior to 
screen is allowed.
 ► Current HCV or HBV (HBcAb- positive,HBsAg- negative is permitted; 
HCV antibody positive with HCV RNA or HCV antigen negative for ≥6 
months following treatment or spontaneous clearance is permitted).
 ► Other chronic liver disease, including but not exclusively, cirrhosis,* 
alcohol- related liver disease,† autoimmune hepatitis, primary bil-
iary cirrhosis, primary sclerosing cholangitis, haemochromatosis, 
Wilson’s disease, alpha-1 antitrypsin deficiency and drug- induced 
non- cirrhotic portal hypertension, as deemed by a hepatologist.
 ► Alanine aminotransferase or aspartate aminotransferase of 
>205 IU/L.
 ► Severe renal insufficiency (creatinine clearance of <30 mL/min).
 ► HIV-2 infection.
 ► Known allergy or intolerance to MVC or its constituents, including 
hypersensitivity to peanuts or soya.
 ► If female, pregnancy or breast feeding.
 ► Individuals currently taking medications or herbal agents that are 
contraindicated with MVC, including St John’s wort.
*Confirmed on biopsy, appearance on imaging (nodular liver with features of 
portal hypertension, such as splenomegaly of >13 cm and/or varices) or liver 
stiffness measurement score (>13 kPa).
†Includes liver disease in the presence of excess alcohol intake as defined 
according to European Association for the Study of the Liver guidelines 2016 
(ie, >20 g/day or >17 units/week for women and >30 g/day or >26 units/week 
for men).
rationale for primary outcome measures
Primary outcome measures will assess the feasibility and 
acceptability of addition of MVC to effective cART in a 
cohort of PLWH as a possible therapy for NAFLD. Accept-
ability will be considered through evaluation of partici-
pant recruitment rate, retention rate and adherence. 
Should feasibility and acceptability be confirmed, this 
would support the establishment of a larger, randomised, 
double- blind, placebo- controlled study to assess the effi-
cacy of the intervention.
rationale for secondary outcome measures
Measures of the efficacy of MVC on a combination of 
non- invasive markers of hepatic inflammation and 
fibrosis will be identified, including the ELF score and 
median liver stiffness measurement and controlled 
attenuation parameter (CAP) scores on Fibroscan. 
Invasive procedures have been avoided, as liver biopsy 
would deter potential participants, particularly those 
without advanced liver disease.
trIAl dEsIgn
This is a phase IV, open- label, randomised, dual- arm feasi-
bility study. Randomisation will be stratified according to
1. Current exposure or past history of ≥6 months’ expo-
sure to protease inhibitor (PI)- containing antiretrovi-
ral therapy versus no current exposure and <6 months 
past exposure to PI- containing therapy.
2. BMI of ≥25 versus <25.
3. Current exposure to a lipid- lowering agent (eg3- 
hydroxy-3- methyl- glutaryl- coenzyme A (HMG CoA) 
reductase inhibitors, eg, statins; cholesterol absorption 
inhibitors, eg, ezetimibe; bile acid- binding drugs, eg, 
cholestyramine; fibrates; and omega 3 fatty acids).
4. Diabetes mellitus (DM) status (1 or 2 vs no DM)
Stratification will be undertaken to balance the treat-
ment groups on important prognostic factors (ie, to 
prevent confounding), given that high BMI, DM2 and 
concurrent administration of PIs1 have been associated 
with faster hepatic fibrosis progression. Statin use has 
conversely been associated with relative protection from 
fibrosis.21
Blinding will not be used for this feasibility study, 
although results may inform the design of a subsequent 
larger, blinded placebo- controlled randomised controlled 
trial investigating efficacy of the intervention. However, it 
is unlikely that there will be behavioural differences in 
the MVC versus non- MVC group, which would change 
risk of fibrosis progression (such as dietary modifications, 
increase in exercise or reduction in alcohol consump-
tion). Therefore, the use of placebo is not considered 
essential.
ElIgIbIlIty CrItErIA
Inclusion and exclusion criteria are shown in boxes 3 and 4.
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Demographic data and medical history, 




Vital signs X† X† X† X† X† X† X† X†
Physical examination, including height, 
weight and waist circumference
X‡ X‡§ X‡§ X‡§ X‡§ X‡§ X‡§
ECG X
Urine dip¶ and pregnancy test (for WOCBP) X X X X X X X
Concomitant medications X X X X X X X X
HIV- associated conditions X X X X X X X
Symptom and AE review X X X X X X X X
Diet and exercise history**  X X X X
CLDQ:NAFLD, SF-36 and WPAI:SHP 
questionnaires
 X X X X
ELF score  X X X X
CD4/CD8 T- cell count X X X X
HIV-1 RNA level X X X X X X X
Proviral DNA tropism††  X
Haematology‡‡ X X X X X X X X
Routine chemistry§§ X X X X X X X X
Fasting chemistry¶¶  X X X X
Additional chemistry*** X X X X
HIV, HBV and HCV serology††† X
Full liver screen‡‡‡ X
Ultrasound liver§§§ X
Fibroscan¶¶¶ X X X X
CT liver:spleen attenuation ratio****  X X
Drug dispensation††††  X X X X X
*Week 4 visit only for individuals receiving MVC. Blood is unfasted.
†Heart rate, respiratory rate, temperature, BP, lying and standing BP (postural BP at screening only and to be repeated if history indicates).
‡Height only at screening; weight and waist circumference at every visit except week 4.
§Symptom directed physical examination only.
¶Point of care urine dip for haematuria, proteinuria, glycosuria, leucocytes and nitrites.
**Dietary history will be daily intake of olive oil, fruit, vegetables or salad, legumes, fish, wine, meat, white bread, rice and whole- grain bread.29 Exercise history will be the number of 
times per week exercise is undertaken, number of minutes of exercise per episode and type of exercise.
††If no result within the preceding 24 weeks.
‡‡Haemoglobin, white cell count and differential, eosinophils and platelets.
§§Sodium, potassium, chloride, creatinine, urea, alanine aminotransferase, aspartate aminotransferase, bilirubin, alkaline phosphatase, gamma glutamyltransferase, albumin, 
phosphate, creatine kinase, glucose (screening, weeks 4, 24 and 72), lipids (total cholesterol, HDL, LDL and TGs) (weeks 24 and 72 only).
¶¶Fasting glucose and fasting lipids (total cholesterol, HDL, LDL, TGs).
***Haemoglobin A1c.
†††HCV antibody, HCV RNA or HCV antigen, HBsAg; if no prior record of result: HBcAb. HIV antibody- antigen only if no previous documented result.
‡‡‡If no previous record of result: INR, ferritin, caeruloplasmin, copper, thyroid function, alpha-1 antitrypsin, antimitochondrial antibodies, antinuclear antibodies, antismooth muscle 
antibody, antiliver/kidney/microsomal antibodies-1 and coeliac serology.
§§§If no previous imaging (ultrasound, CT or MRI) result confirming fatty liver in the preceding 24 weeks.
¶¶¶Includes both median stiffness and controlled attenuation parameter scores, to be performed within 7 days of the study visit.
****Optional. To be performed within 7 days of the study visit. Preference is for the 7 days prior to baseline.
††††Only for individuals assigned to the MVC group.
AE, adverse event; ART, antiretroviral therapy; BP, blood pressure; CK, creatine kinase; CLDQ:NAFLD, chronic liver disease questionnaire for non- alcoholic fatty liver disease; ELF, 
enhanced liver fibrosis; HBsAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HDL, high- density lipoprotein; INR, international normalised ratio; LDL, low- density 
lipoprotein; MVC, maraviroc; SF-36, 36- Item Short Form Survey; TG, triglycerides; US, ultrasound; WOCBP, women of childbearing potential; WPAI:SHP, Work Productivity and Activity 
Impairment: Specific Health Problem Questionnaire.
trIAl ProCEdurEs
The schedule of assessments is summarised in table 1.
rECruItMEnt
Sixty participants will be recruited in seven UK National 
Health Service (NHS) HIV clinics. Potentially eligible 
individuals with evidence of hepatic steatosis on imaging 
or biopsy performed as part of routine clinical care will 
be identified by clinical staff, either from the direct care 
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team or by research clinicians working in the same HIV 
team. It is envisaged that ultrasound will be used to iden-
tify possible participants as this is the recommended 
first- line diagnostic imaging procedure for NAFLD,22 
although some cases, particularly individuals with mild 
hepatic steatosis, may be missed. It is also emphasised that 
this trial will recruit only PLWH with NAFLD who do not 
have cirrhosis. People with cirrhosis have been excluded 
in order that the study population is not too heteroge-
neous. However, people with cirrhosis would be included 
in a larger randomised controlled trial.
The following approach will be used for identification 
of participants: (1) review of a database of patients in the 
HIV department with NAFLD, (2) preidentification of 
patients due to attend a routine prearranged follow- up 
appointment in the HIV or hepatology service and (3) 
review of medical notes during routine clinical follow- up. 
Individuals will be contacted either in person in the clinic 
or by telephone. Anonymised information on individuals 
who are contacted but are not randomised will include 
age, gender, ethnicity, the reason for lack of eligibility for 
participation or if they are eligible but declined.
study vIsIts
Study visits and assessments will take place according to 
the schedule in table 1.
screening visit
Potentially eligible participants will be invited to attend 
for an appointment, having been provided with a partici-
pant information sheet. Adequate time (at least 24 hours) 
will be allowed for questions and to consider the study 
before agreeing to participate. Written informed consent 
will be received by the investigator. Results of screening 
evaluations must be available within 42 days of randomis-
ation and eligibility must be established.
randomisation scheme
Subjects will be randomised 1:1 into the MVC and non- 
MVC groups at the baseline visit. In addition, there will be 
stratification according to the factors outlined above. The 
web- based Sealed Envelope system will be used to allocate 
individuals randomly to the MVC or non- MVC groups. 
The statistician will provide the randomisation list and 
the HEPatic fibrosis in people living with HIV-1 and non- 
alcoholic fatty liver disease randomised to receiving opti-
mised background therapy (OBT) plus MARaviroC or OBT 
(HEPMARC) Randomisation Guide will be followed by the 
study team.
Withdrawal
A participant is free to withdraw from the study at any 
time. In addition, the investigator may decide, for reasons 
of medical prudence, to withdraw a subject. If a subject 
discontinues study medication dosing, every attempt 
should be made to keep the subject in the study and 
continue to perform the required study- related proce-
dures and follow- up procedures. If this is not possible or 
acceptable to the subject or investigator, the subject may 
be withdrawn from the study.
Study medication may also be discontinued in the 
following instances:
1. If the subject withdraws his/her consent.
2. If the investigator considers that it is in the best inter-
est of the subject (eg intercurrent illness or unaccept-
able toxicity) for him/her to withdraw consent.
3. The subject fails to comply with the protocol require-
ments or fails to cooperate with the investigator.
4. Pregnancy during the course of the study.
trIAl MEdICAtIon
name and description of the investigational medicinal product 
Maraviroc (Celsentri)
In the UK, MVC is a licensed drug indicated with other 
antiretroviral medications for treatment- experienced 
adults infected with only CCR5- tropic HIV-1. It is supplied 
as a film- coated tablet. The recommended dose is 150, 
300 or 600 mg two times per day, depending on inter-
actions with coadministered antiretroviral therapy and 
other medicinal products, according to the Summary of 
Product Characteristics (SPC).23
dosage schedules
For those randomised to receiving MVC, dosing will 
be according to SPC recommendations. The total dose 
will be determined according to interactions with other 
medications. Modification of the dose of MVC will not 
be undertaken except where indicated due to potential 
drug–drug interactions (DDIs) with concomitant medica-
tions. Where a participant initiates a new medication or 
discontinues an existing medication, the investigator will 
confirm whether or not a DDI could occur and hence the 
need for any dose modification of MVC.
For women of childbearing potential, contraception 
needs to be used for the duration of the study and for 30 
days after the end of the trial. This includes the following, 
according to the woman’s preference and DDIs with 
concomitant medications:
 ► Intrauterine device.
 ► Hormonal- based contraception (pill, contraceptive 
injection, implant and intrauterine system).
 ► Double- barrier contraception (condom and occlusive 
cap, eg, diaphragm or cervical cap with spermicide).
 ► True abstinence.
Assessment of compliance
Compliance will be assessed through
1. Self- reporting of doses of MVC taken via a diary card.
2. Pill counting at each visit by a pharmacist and recording 
of the number of pills returned.
Participants will bring in all pill bottles at each study visit. 
The total number of investigational medicinal product 
(IMP) pills remaining at each visit will be counted and 
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then returned to the participant to take until the bottle is 
finished.
The percentage of IMP compliance for each participant 
will be calculated. Where this figure is <80%, this will lead 
to a likely recommendation to discontinue IMP, although 
this will be at the discretion of the principal investigator. 
In all circumstances, every effort will be made to continue 
to follow- up the participant on the study. Of note, where 
a discrepancy exists between self- reported compliance 
and compliance identified via pill counting, any deci-
sion to discontinue IMP will rest with the study principal 
investigator.
toxicity management
In the event of toxicity or intolerance to MVC in this study, 
subjects will be managed as in standard clinical practice. 
This may involve discontinuing MVC in some cases.
AdvErsE EvEnts
Adverse events (AEs) observed by the investigator or 
reported by the subject and any remedial action taken will 
be recorded in the subject’s case report form (CRF) and 
should be verifiable in the subject’s notes throughout the 
study. The nature of each event, time of onset after drug 
administration, duration and severity will be documented, 
together with the investigator’s opinion of the causal rela-
tionship to the treatment (unrelated, unlikely, possible, 
probable and definite).
All subjects experiencing AEs, whether considered asso-
ciated with the use of the study medication or not, must 
be monitored until the symptoms subside and any clini-
cally relevant changes in laboratory values have returned 
to baseline or until there is a satisfactory explanation for 
the changes observed. Clinically significant changes in 
physical examination and blood safety profiles should 
also be recorded as AEs.
Assessment of intensity
Severity should be recorded and graded according to the 
AIDS Clinical Trial Group Grading Scale.
AEs, serious adverse events (SAEs), adverse reactions 
(ARs), serious ARs and suspected unexpected serious ARs 
may be directly observed and reported spontaneously by 
the subject or by questioning the subject at each study 
visit. These will be followed up until they are resolved 
or the subject’s participation in the study ends (ie, until 
the final CRF is completed for that subject). In addition, 
all SAEs assessed by the investigator as possibly related 
to the investigational medication should continue to be 
followed up even after the subject’s participation in the 
study is over.
Such events should be followed up until resolution or 
until no further change can reasonably be expected.
data safety and monitoring board (dsMb)
A group of independent clinicians and a statistician 
comprise the DMSB. The DSMB will periodically review 
overall safety data according to its charter (available from 
Brighton Clinical Trials Unit), in addition to all other 
study parameters. It will determine patterns and trends 
of events, or identify safety issues, which would not be 
apparent on an individual case basis.
Post-trIAl CArE
Post trial, all individuals will be provided with standard of 
care interventions indicated for the treatment of NAFLD 
in line with current UK National Institute for Health and 
Care Excellence (NICE) guidelines.
All participating individuals will be advised, as part of 
the informed consent process, that MVC would be discon-
tinued post- trial. Where individual patients and/or their 
treating clinicians request the continuation of MVC post 
trial, this request will be considered on a case by case basis 
by the HIV multidisciplinary team at each site. Although 
the primary objective of the current study does not include 
efficacy of the drug, a substantial improvement in hepatic 
fibrosis markers in individual patients is likely to strengthen 
the case for continuation of drug, which will be made based 
on its need within the overall HIV treatment regimen.
In addition, any beneficial effect identified in the trial 
will inform the establishment of a larger study on the 
effect of MVC on NAFLD in PLWH. This, in turn, may 
lead to a change to national recommendations with the 
possibility that MVC could be prescribed to patients 
through existing NHS funding schemes.
stAtIstICs And dAtA AnAlysIs
sample size calculation
As this is a feasibility study, no formal sample size calcula-
tion has been conducted. Results may be used to estimate 
the variability of the treatment effect of MVC on the ELF 
score, which may inform the sample size calculation for a 
larger, randomised placebo- controlled trial.
In a previous biopsy study, a unit increase of 1 in the 
ELF score was associated with a 2.5- fold increased risk of a 
liver- related event (adjusted for age and stage of fibrosis), 
and therefore a unit increase of 1 is deemed to represent a 
clinically important entity.24 Other studies have confirmed 
the accuracy of the ELF score in the assessment of hepatic 
fibrosis in PLWH and in those with NAFLD.25–28 Assuming 
the SD of the ELF score is 1.12, with 20 patients in each 
group for the analysis, a difference in ELF of 1 point can 
be estimated with a 95% CI from 0.6 to 1.4. Assuming 
an attrition rate of 33%, a target of 30 individuals will be 
recruited per group.22
A t- method will be used to estimate the difference 
in ELF scores, together with 95% CIs, between the two 
groups. P values will not be presented.
Planned recruitment rate
An estimated three to four individuals will be recruited 
per month over an 18- month period. This takes into 
account the following factors:
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 ► The estimated prevalence of NAFLD among HIV- 
infected cohorts is predicted to be 30%. Although 
many individuals are undiagnosed, recruitment at 
seven sites with >5000 HIV- infected patients overall 
is expected to yield at least 200 who have been diag-
nosed with NAFLD on previous imaging as part of 
routine clinical care.
 ► All PLWH are expected to attend a minimum of 
two medical appointments per year. For a minimum 
of 5000 individuals, a monthly target of four to five 
is predicted to be feasible, allowing for one to two 
screen failures per month, leaving three to four to be 
recruited.
statistical analysis plan
Summary of baseline data and flow of patients
Baseline comparability between the two randomised groups 
will be described by considering the variables below.
For categorical data, percentage will be presented. For 
continuous data, the mean or median will be presented 
for variables following a normal and non- normal distribu-
tion, respectively, in addition to the IQR.
 ► Age.
 ► Per cent male.
 ► Per cent of each ethnicity.
 ► Duration of HIV infection.
 ► Nadir CD4 count.
 ► Baseline CD4 count.
 ► Per cent with undetectable HIV viral load.
 ► Per cent receiving PI- based cART versus non- PI- based 
cART.
 ► Per cent receiving concomitant lipid- lowering therapy.
 ► BMI.
 ► Waist circumference.
 ► Weight.
 ► Blood pressure.




 ► Fasting TG.
 ► Fasting LDL.
 ► Fasting HDL.
 ► Fasting total cholesterol.
 ► Fasting HDL:cholesterol ratio.
 ► Baseline ELF score.
 ► Baseline Fibroscan stiffness result.
 ► Baseline Fibroscan CAP score.
 ► % with a CT liver:spleen attenuation ratio < 1.0.
 ► Baseline diet score.
See figure 1 for the Consolidated Standards of 
Reporting Trials flow diagram for this study.
Feasibility outcome analyses
All analyses will be performed on available cases according 
to intention- to- treat (ITT) principles. Therefore, all indi-
viduals randomised within the study (including those subse-
quently withdrawn) will be included in outcome analyses.
The following analyses will be presented:
1. Proportion of eligible individuals approached who are 
successfully recruited. It is envisaged that a recruitment 
rate of at least 50% will achieved. This takes into account 
the likelihood that a proportion of potential recruits will 
decline, for example, owing to the requirement for two 
times per day pill taking.
2. Monthly participant recruitment rate. This is expected 
to be at least two participants consistently per month, 
with an average of three to four.
3. Participant retention in the study at 48 and 96 weeks 
in the MVC and non- MVC assigned groups. This is ex-
pected to be at least 65% (cf 35% discontinuation in 
the Maraviroc versus Optimized Therapy in Viremic 
Antiretroviral Treatment- Experienced Patients (MO-
TIVATE) study10).
4. Proportion of participants for whom there are missing 
data at 48 and 96 weeks in the MVC and non- MVC as-
signed groups. This is expected to be less than 20% for 
all participants.
5. Proportion of participants reporting AEs at 48 and 96 
weeks in the MVC and non- MVC assigned groups. This 
is expected to be less than 10% based on the SPC for 
MVC.23
6. Level of self- reported adherence to the study drug at 
48 and 96 weeks in those allocated to the MVC group. 
This is expected to be greater than 90%.
Secondary outcome analysis
The analysis of the secondary outcomes, shown in box 2, 
will be presented as the estimated difference and 95% CI 
between groups using a t- method for continuous variables 
and as exact 95% binomial CIs for categorical variables, 
from baseline to 48 and 96 weeks.
In the event of missing data, only available data will be 
included in the analyses.
dAtA hAndlIng, ConfIdEntIAlIty And MonItorIng
An electronic data management system MACRO will 
be used in this study. All information will be recorded 
in source data and documentation that will be filed in 
patients’ notes. Direct access to data will be granted to 
authorised representatives from the sponsor, host institu-
tion and the regulatory authorities when appropriate to 
permit trial- related monitoring, audits and inspections. A 
specific trial monitoring plan has been developed for the 
study (available from Brighton Clinical Trials Unit).
All investigators and trial site staff will comply with the 
requirements of the Data Protection Act 1998.
Personal information will be collected, kept secure and 
maintained. This will involve the creation of coded, deper-
sonalised data, secure maintenance of the data and the 
linking code in separate locations using encrypted digital 
files and limiting access to the minimum number of indi-
viduals necessary for quality control, audit and analysis. The 
confidentiality of data will be preserved when the data are 
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Figure 1 Consolidated Standards of Reporting Trials flow diagram for the HEPatic fibrosis in people living with HIV-1 and non- 
alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus MARaviroCor OBT (HEPMARC) 
study.
transmitted to sponsors and coinvestigators by using only 
pseudynomised codes rather than personal identifiable 
information. Data will be stored for 25 years.
EthICs And dIssEMInAtIon
This study has been approved by the Research Ethics 
Committee, London Dulwich, UK (REC reference 17/
LO/2093). Protocol amendments will be communi-
cated to all relevant parties. Results of the study will 
be written up and submitted for publication in both 
HIV and hepatology journals, as well as disseminated 
through HIV community groups. Study data will be 
made available on reasonable request to the Brighton 
Clinical Trials Unit.
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